Foamix Pharmaceuticals Ltd. (FOMX) financial statements (2022 and earlier)

Company profile

Business Address 2 HOLZMAN ST.
REHOVOT, 76704
State of Incorp.
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:72,10798,58416,206
Cash and cash equivalents43,75927,86815,956
Short-term investments28,34870,71651,240
Other undisclosed cash, cash equivalents, and short-term investments  (50,990)
Restricted cash and investments1,259518540
Receivables1351,066996
Inventory, net of allowances, customer advances and progress billings1,356  
Inventory1,356  
Derivative instruments and hedges, assets (3)11
Other undisclosed current assets1,5571,00251,751
Total current assets:76,414101,16769,504
Noncurrent Assets
Operating lease, right-of-use asset1,694
Property, plant and equipment2,8852,2352,042
Long-term investments and receivables 1508,533
Long-term investments 1508,533
Restricted cash and investments 133143
Other noncurrent assets1664632
Total noncurrent assets:4,7452,56410,750
TOTAL ASSETS:81,159103,73180,254
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities27,9644,1413,730
Accounts payable19,35229270
Accrued liabilities3,3813511,622
Employee-related liabilities5,2313,4982,038
Debt1,092  
Deferred revenue and credits62
Other undisclosed current liabilities2706,3276,436
Total current liabilities:29,32610,46810,228
Noncurrent Liabilities
Long-term debt and lease obligation33,378  
Long-term debt, excluding current maturities32,725  
Operating lease, liability653
Other undisclosed noncurrent liabilities8801,0811,425
Total noncurrent liabilities:34,2581,0811,425
Total liabilities:63,58411,54911,653
Stockholders' equity
Stockholders' equity attributable to parent17,57592,18268,601
Common stock2,6592,3311,576
Additional paid in capital325,498305,303208,364
Accumulated other comprehensive income (loss)5(43)(58)
Accumulated deficit(310,587)(215,409)(141,281)
Total stockholders' equity:17,57592,18268,601
TOTAL LIABILITIES AND EQUITY:81,159103,73180,254

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
Revenues4433,5953,669
Revenue, net3,669
Net investment income589297 
Cost of revenue  (13)
Gross profit:4433,5953,656
Operating expenses(96,316)(78,487)(69,270)
Operating loss:(95,873)(74,892)(65,614)
Interest and debt expense(921)  
Loss from continuing operations before equity method investments, income taxes:(96,794)(74,892)(65,614)
Other undisclosed income from continuing operations before income taxes1,4409411,063
Loss from continuing operations before income taxes:(95,354)(73,951)(64,551)
Income tax expense (benefit)176(212)(1,164)
Net loss available to common stockholders, diluted:(95,178)(74,163)(65,715)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
Net loss:(95,178)(74,163)(65,715)
Comprehensive loss:(95,178)(74,163)(65,715)
Other undisclosed comprehensive income, net of tax, attributable to parent48504
Comprehensive loss, net of tax, attributable to parent:(95,130)(74,113)(65,711)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: